NewGenIvf Group (NIVF) has captured analyst attention with a dramatic reassessment of its valuation potential. The consensus price target has climbed to $76.50 per share, marking a remarkable 400% jump from the previous estimate of $15.30 established back in November 2025. This substantial upward revision reflects growing confidence among research teams tracking the reproductive health sector.
Analyst Price Projections Show Wide Range Around 400% Lift
The current price target represents a consensus view synthesized from multiple analyst contributions. Individual projections vary, with estimates ranging from $75.75 on the conservative end to $78.75 on the optimistic side. When measured against NIVF’s latest closing price of $1.45, the implied upside reaches approximately 5,176%, underscoring the gap between current market valuation and analyst expectations. This substantial 400% revision upward from prior guidance signals a meaningful shift in how market observers view the company’s prospects.
Fund and institutional participation in NIVF has shown notable changes recently. Currently, three funds or institutions report positions in the stock, though this figure has decreased from earlier periods. The aggregate institutional portfolio allocation dedicated to NIVF stands at 0.00%, while total institutional shareholdings have declined 96.90% to reach 0K shares over the past three months. Among reported holders, SBI Securities maintains a stake representing 0.03% ownership, while Bank Of America’s position accounts for 0.00% of shares outstanding. These shifting institutional dynamics suggest ongoing evaluation of NIVF’s investment merits among professional managers.
Research data aggregated through platforms like Fintel tracks these ownership patterns and analyst sentiment shifts, providing granular visibility into how the investment community reassesses opportunities like the 400% price target increase now surrounding NIVF.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
NIVF Stock Surges with 400% Price Target Increase to $76.50
NewGenIvf Group (NIVF) has captured analyst attention with a dramatic reassessment of its valuation potential. The consensus price target has climbed to $76.50 per share, marking a remarkable 400% jump from the previous estimate of $15.30 established back in November 2025. This substantial upward revision reflects growing confidence among research teams tracking the reproductive health sector.
Analyst Price Projections Show Wide Range Around 400% Lift
The current price target represents a consensus view synthesized from multiple analyst contributions. Individual projections vary, with estimates ranging from $75.75 on the conservative end to $78.75 on the optimistic side. When measured against NIVF’s latest closing price of $1.45, the implied upside reaches approximately 5,176%, underscoring the gap between current market valuation and analyst expectations. This substantial 400% revision upward from prior guidance signals a meaningful shift in how market observers view the company’s prospects.
Institutional Portfolio Positioning Reflects Mixed Sentiment
Fund and institutional participation in NIVF has shown notable changes recently. Currently, three funds or institutions report positions in the stock, though this figure has decreased from earlier periods. The aggregate institutional portfolio allocation dedicated to NIVF stands at 0.00%, while total institutional shareholdings have declined 96.90% to reach 0K shares over the past three months. Among reported holders, SBI Securities maintains a stake representing 0.03% ownership, while Bank Of America’s position accounts for 0.00% of shares outstanding. These shifting institutional dynamics suggest ongoing evaluation of NIVF’s investment merits among professional managers.
Research data aggregated through platforms like Fintel tracks these ownership patterns and analyst sentiment shifts, providing granular visibility into how the investment community reassesses opportunities like the 400% price target increase now surrounding NIVF.